- Home
- FATN vs CHRS Comparison
FATN vs CHRS Comparison
Compare FATN & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FATN
- CHRS
- Stock Information
- Founded
- FATN 1989
- CHRS 2010
- Country
- FATN United States
- CHRS United States
- Employees
- FATN N/A
- CHRS N/A
- Industry
- FATN
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FATN
- CHRS Health Care
- Exchange
- FATN NYSE
- CHRS Nasdaq
- Market Cap
- FATN 132.0M
- CHRS 112.5M
- IPO Year
- FATN 2025
- CHRS 2014
- Fundamental
- Price
- FATN $8.66
- CHRS $0.77
- Analyst Decision
- FATN
- CHRS Buy
- Analyst Count
- FATN 0
- CHRS 3
- Target Price
- FATN N/A
- CHRS $4.68
- AVG Volume (30 Days)
- FATN 111.3K
- CHRS 1.5M
- Earning Date
- FATN 01-01-0001
- CHRS 05-12-2025
- Dividend Yield
- FATN N/A
- CHRS N/A
- EPS Growth
- FATN 56.77
- CHRS N/A
- EPS
- FATN 0.37
- CHRS N/A
- Revenue
- FATN $17,876,645.00
- CHRS $272,251,000.00
- Revenue This Year
- FATN N/A
- CHRS N/A
- Revenue Next Year
- FATN N/A
- CHRS $19.78
- P/E Ratio
- FATN $24.38
- CHRS $1.83
- Revenue Growth
- FATN 13.17
- CHRS 19.87
- 52 Week Low
- FATN $5.60
- CHRS $0.66
- 52 Week High
- FATN $23.27
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- FATN N/A
- CHRS 39.42
- Support Level
- FATN N/A
- CHRS $0.74
- Resistance Level
- FATN N/A
- CHRS $0.82
- Average True Range (ATR)
- FATN 0.00
- CHRS 0.06
- MACD
- FATN 0.00
- CHRS -0.00
- Stochastic Oscillator
- FATN 0.00
- CHRS 23.41
About FATN FATPIPE INC
Fatpipe Inc is a pioneer in enterprise-class, application-aware, secure SD-WAN solutions for organizations, including enterprises, communication service providers, security service providers, government organizations, and other middle-market companies. It is engaged in delivering principal enterprise-class networking software technology. The company is dedicated to continually improving the way organizations connect, ensuring their networks are secure, reliable, and supporting their continued success. Its commitment lies in empowering its customers with a seamless and dependable connectivity infrastructure that safeguards their critical data and fosters business continuity. Further, the company's goal is to ensure its customers have unparalleled insights into their network operations.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.